Gyki-53655

Gyki-53655

SCHEMBL351325

CNC(=O)N1N=C(c2ccc(N)cc2)c2cc3c(cc2CC1C)OCO3

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA2 P42262 2/20 1.00
GRIA1 P42261 1/20 1.00
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
CYP1A2 P05177 3/20 0.56
CYP3A4 P08684 3/20 0.56
CYP2D6 P10635 3/20 0.56
MAPT P10636 3/20 0.56
KDM4E B2RXH2 2/20 0.56
MAPK1 P28482 2/20 0.56
HSD17B10 Q99714 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
ALDH1A1 P00352 2/20 0.56
THRB P10828 1/20 0.56
TSHR P16473 1/20 0.56
CYP2C9 P11712 2/20 0.54
NFKB1 P19838 2/20 0.54
CYP2C19 P33261 2/20 0.54
HIF1A Q16665 2/20 0.54
LMNA P02545 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gyki-53655 SCHEMBL8192023 1.00 GRIA2 (1.00) GRIA2GRIA1MEN1KMT2ACYP1A2
Gyki-53655 SCHEMBL30259941 1.00 GRIA2 (1.00) GRIA2GRIA1MEN1KMT2ACYP1A2
Gyki-53655 SCHEMBL25271920 0.99 GRIA2 (0.98) GRIA2GRIA1MEN1KMT2ACYP1A2
Gyki-53655 SCHEMBL30389810 0.99 GRIA2 (0.98) GRIA2GRIA1MEN1KMT2ACYP1A2
SCHEMBL5881321 0.89 GRIA2 (0.81) GRIA2GRIA1MEN1KMT2ACYP1A2
SCHEMBL30259935 0.89 GRIA2 (0.81) GRIA2GRIA1MEN1KMT2ACYP1A2
Talampanel SCHEMBL118011 0.89 GRIA2 (0.80) GRIA2GRIA1MEN1KMT2ACYP1A2
SCHEMBL118013 0.89 GRIA2 (0.80) GRIA2GRIA1MEN1KMT2ACYP1A2
Talampanel SCHEMBL118012 0.89 GRIA2 (0.80) GRIA2GRIA1MEN1KMT2ACYP1A2
Talampanel SCHEMBL30272868 0.89 GRIA2 (0.80) GRIA2GRIA1MEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024102177-A1 COMBINATION THERAPIES FOR THE TREATMENT OF BRAIN CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-05-16 WO claimed
EP-2255798-B1 FTY720 for use in the treatment of optic neuritis NOVARTIS AG (CH) 2014-12-24 EP claimed
WO-2011076946-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER Universidad Del País Vasco (ES) 2011-06-30 WO claimed
US-7192931-B2 Treatment of demyelinating diseases NEUREN PHARMACEUTICALS LTD. (NZ) 2007-03-20 US claimed
US-7101879-B2 Treatments for neurotoxicity in Alzheimer's Disease MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2006-09-05 US claimed
US-20050182047-A1 Treatment of demyelinating disorders EISAI CO., LTD. (JP) 2005-08-18 US claimed
US-20040204347-A1 Treatment of demyelinating disorders EISAI CO., LTD. (JP) 2004-10-14 US claimed
US-6797692-B1 Use of glutamate antagonists for the treatment of cancer IKONOMIDOU HRISSANTHI (DE) 2004-09-28 US claimed
WO-2004069195-A2 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISORDERS OF THE AIRWAYS IVAX CORPORATION (US) 2004-08-19 WO claimed
US-20040152694-A1 Methods and compositions for treating inflammatory disorders of the airways IVAX DRUG RESEARCH INSTITUTE, LTD. 2004-08-05 US claimed
EP-1015013-A1 TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE BY beta-AMYLOID PEPTIDES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2000-07-05 EP claimed
WO-2000024395-A1 NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER IKONOMIDOU HRISSANTHI (DE) 2000-05-04 WO claimed
WO-2000001376-A2 PHARMACEUTICAL COMPOSITIONS AND THEIR USES FOR TREATMENT OF DEMYELINATING DISORDERS EISAI CO., LTD (JP) 2000-01-13 WO claimed
WO-1998030229-A1 TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE BY β-AMYLOID PEPTIDES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1998-07-16 WO claimed
US-5639751-A N-acyl-2,3-benzodiazepine derivatives for treating acute and chronic neurodegenerative disorders CYOGYSZERKUTATO INTEZET KFT (HU) 1997-06-17 US claimed
US-5604223-A TREATING EPILEPSY, NERVOUS SYSTEM DISORDER GYOGYSZERKUTATO INTEZET KFT. (HU) 1997-02-18 US claimed
US-5536832-A CENTRAL NERVOUS SYSTEM DISORDERS GYOGYSZERKUTATO INTEZET KFT (HU) 1996-07-16 US claimed
US-5521174-A ANTISPASMODIC AGENTS GYOGYSZERKUTATO INTEZET KV. (HU) 1996-05-28 US claimed
US-5519019-A NERVOUS SYSTEM DISORDERS AND MUSCLE RELAXANTS GYOGYSZERKUTATO INTEZET (HU) 1996-05-21 US claimed
US-5459137-A Muscle relaxants, anticonvulsants, neuroprotective agents GYOGYSZERKU-TATO INTEZET KFT (HU) 1995-10-17 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204347-A1 Treatment of demyelinating disorders GRIK4, GRIK5, PMP22 GRIA2 21/4885GRIA1 20/4885MEN1 3154/4885
US-20040152694-A1 Methods and compositions for treating inflammatory disorders of the airways LTB4R2, LTB4R, LTC4S GRIA2 2341/4885GRIA1 2085/4885MEN1 4621/4885
US-20050182047-A1 Treatment of demyelinating disorders GRIK4, PMP22, GRIK5 GRIA2 21/4885GRIA1 19/4885MEN1 3073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.